Next Article in Journal
A Monoclonal Antibody to Human DLK1 Reveals Differential Expression in Cancer and Absence in Healthy Tissues
Next Article in Special Issue
Reverse Signaling Contributes to Control of Chronic Inflammation by Anti-TNF Therapeutics
Previous Article in Journal / Special Issue
TNFR1 and TNFR2 Expression and Induction on Human Treg Cells from Type 1 Diabetic Subjects
Open AccessReview

Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy

Institute of Cell Biology and Immunology, University of Stuttgart, Allmandring 31, 70569 Stuttgart, Germany
Author to whom correspondence should be addressed.
Academic Editor: Dimiter S. Dimitrov
Antibodies 2015, 4(1), 48-70;
Received: 29 January 2015 / Revised: 23 February 2015 / Accepted: 27 February 2015 / Published: 6 March 2015
(This article belongs to the Special Issue TNF in the Regulation of Immune Cells)
Deregulation of the tumor necrosis factor (TNF) plays an important role in the initiation and perpetuation of chronic inflammation and has been implicated in the development of various autoimmune diseases. Accordingly, TNF-inhibitors are successfully used for the treatment of several diseases, such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. However, total inhibition of TNF can cause severe side effects such as an increased risk of inflammation and reactivation of tuberculosis. This is likely due to the different actions of the two TNF receptors. Whereas TNFR1 predominantly promotes inflammatory signaling pathways, TNFR2 mediates immune modulatory functions and promotes tissue homeostasis and regeneration. Therefore, the specific blockage of TNFR1 signaling, either by direct inhibition with TNFR1-selective antagonists or by targeting soluble TNF, which predominantly activates TNFR1, may prevent the detrimental effects associated with total TNF-inhibitors and constitute a next-generation approach to interfere with TNF. View Full-Text
Keywords: antibodies; autoimmune diseases; inflammation; neurodegeneration; TNF; TNF receptors antibodies; autoimmune diseases; inflammation; neurodegeneration; TNF; TNF receptors
Show Figures

Figure 1

MDPI and ACS Style

Fischer, R.; Kontermann, R.E.; Maier, O. Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy. Antibodies 2015, 4, 48-70.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop